Form 4: ARS Pharmaceuticals Director Rajeev Dadoo Granted 30,000 Stock Options

ARS Pharmaceuticals, Inc. Director Rajeev Dadoo was granted 30,000 stock options with an exercise price of $17.26, vesting by June 2026.

Summary

• Rajeev Dadoo, a Director of ARS Pharmaceuticals, Inc. (SPRY), was granted 30,000 stock options.
• The stock options have an exercise price of $17.26 per share.
• The transaction date for this grant was June 25, 2025.
• The options are set to expire on June 24, 2035.
• The shares subject to the option will vest in full on the earlier of June 25, 2026, or the date of the Issuer's 2026 annual meeting of stockholders.
• Following this reported transaction, Rajeev Dadoo beneficially owns 30,000 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, as it aligns management incentives with shareholder interests for long-term growth. However, it does not represent immediate cash flow or a direct positive financial performance metric for the company itself.

Positives

• The grant of stock options to a director aligns their interests with shareholders, incentivizing long-term performance and value creation.
• The options have a long expiration date of June 24, 2035, providing a substantial window for the company's stock price to appreciate, potentially making the options profitable.

Negatives

• The grant is for stock options, not immediately exercisable shares, meaning there is no immediate cash inflow for the director.
• For the options to be 'in the money' and profitable, ARS Pharmaceuticals' stock price must rise above the exercise price of $17.26 per share.

Risks

• The exact vesting date for the options is subject to the earlier of June 25, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, which has not yet been set by the Board of Directors, introducing a minor uncertainty.

Future Outlook

The vesting schedule indicates that the granted stock options will become fully exercisable on the earlier of June 25, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, signaling a future milestone for the director's equity compensation.

Industry Context

The grant of stock options to a director is a common and standard practice within the pharmaceutical and broader corporate sectors to incentivize leadership and align their long-term interests with those of the company's shareholders. This filing reflects a routine compensation event.

Comparison to Industry Standards

• The granting of stock options to directors is a widely accepted form of non-cash compensation across various industries, including pharmaceuticals, aligning director incentives with long-term shareholder value creation.
• The exercise price of $17.26 is set at the market price on the grant date, which is a standard practice for incentive stock options.
• The 10-year expiration period (until June 24, 2035) is typical for long-term equity incentives granted to executives and directors in publicly traded companies.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with the long-term appreciation of the company's stock price, potentially benefiting shareholders through improved performance.
• Employees/Management: This reflects standard compensation practices for directors, which can be seen as a positive for attracting and retaining high-caliber board members.

Next Steps

• The stock options will vest in full on the earlier of June 25, 2026, or the date of ARS Pharmaceuticals' 2026 annual meeting of stockholders.

Key Dates

Recommendation

Keywords

ARS Pharmaceuticals, SPRY, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Rajeev Dadoo